Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. - Test2 - elhamkhani - TriplyDB

Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.

Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.

http://www.wikidata.org/entity/Q35294150

about

Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere Aedes aegypti Control Strategies in Brazil: Incorporation of New Technologies to Overcome the Persistence of Dengue Epidemics Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus Zika Virus Targets Different Primary Human Placental Cells, Suggesting Two Routes for Vertical Transmission Human antibody response to dengue virus: implications for dengue vaccine design Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies Laboratory-acquired dengue virus infection by needlestick injury: a case report, South Korea, 2014 Recent advances in understanding dengue The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Mechanisms and possible controls of the in utero Zika virus infection: Where is the Holy Grail?A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.Temperature-dependent folding allows stable dimerization of secretory and virus-associated E proteins of Dengue and Zika viruses in mammalian cells.Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection.Zika Virus as an Emerging Neuropathogen: Mechanisms of Neurovirulence and Neuro-Immune Interactions.Fc receptors in antibody-dependent enhancement of viral infections.Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.Macrophage Activation Syndrome-Associated Markers in Severe Dengue.A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development.Intrahost Selection Pressures Drive Rapid Dengue Virus Microevolution in Acute Human Infections.Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity.Epidemiology and characteristics of the dengue outbreak in Guangdong, Southern China, in 2014.Dengue infection.Serum Ferritin: A Backstage Weapon in Diagnosis of Dengue Fever.A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo.Development of Zika Virus Vaccines.The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design.Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.Antibody-dependent enhancement of severe dengue disease in humans.

P2860

Q24261248-70B97FE3-83C1-4A80-ABE8-E4896752CE1D Q24273310-7DBD8D3F-9748-436C-A118-1C0485D91423 Q26247258-3786F47D-A2A3-40CC-94EC-76124435A389 Q26252081-ED591F12-ABB5-42D8-ABC6-05DE4812927D Q26314609-BA6B1EEA-9E36-4F78-945A-93289CABEBFC Q26314715-25A71DBA-7D98-44BC-89F8-4C6854EE5760 Q26315568-57C75F4F-8373-4AE1-BB82-1B7341C6686A Q26766156-E30E93EA-7D53-4009-BBDC-AA1E327C6632 Q26995782-66C7FCD8-BDD5-4A7B-B216-FDAED779D466 Q27654848-AF4DF00D-818F-41C8-9C10-1B57614D3216 Q28733412-AA830BF6-CD84-480C-95EB-56AB68EC4DE7 Q28804076-4C9B9381-9F06-4232-A75B-3F1064F681B8 Q28804225-8DA717AF-2F20-4C40-B20C-57D61FC6E33C Q33650118-DA1C65E4-9C21-428D-83F2-25A34A07A312 Q33681310-E00FC1E3-CF09-4055-BC39-ECA173FAD868 Q33850577-BEDC30FD-3EA4-4CE0-A067-E045C1153855 Q34522384-EB1A77D4-5FC5-4978-961F-8B186FDFC7F6 Q35781300-9CA0F65F-5822-47AB-B1CE-A57B3EC915C0 Q36234359-369CF9F1-9CA8-4CB8-B0BF-91BA96EA17EB Q36434210-568A112C-AE7C-41DA-97C4-46F5618B4FDD Q38157397-0C33B151-3BD1-43EA-88C5-48E2B39CFB08 Q38158918-BA1A7E44-FD4C-48D0-ADB0-0268D2F74D01 Q38615396-EA970E34-A40D-4653-8EBF-3AD174DAC3ED Q38618056-8BF21A8C-2370-4DAD-8E25-5FF4F0C98EFB Q38636217-C2EC8122-CCE0-4648-ABE7-A52B968E7719 Q38704501-0B8F873A-76E7-4809-B18A-FEC78D17FA4F Q38983251-343B9715-59E8-4352-95C2-927D1AFF7DFB Q39535403-D2EE55CA-584C-4740-A86D-A9E7EE1AAA0A Q40038877-56DF828B-7D30-4C82-904F-2F3C0007283A Q40047887-13495CE4-E72D-41E4-B887-342293BA8DCB Q40088326-CC65F74B-E86D-4275-9E5A-05D251C63537 Q40125629-7F9A0350-B803-4591-A325-85AA90A4787C Q42996339-1ADB63FD-70C9-4142-B170-4D6C0F84C37F Q47139015-E969598B-9362-4145-8655-10330E608B1C Q47194469-8621B9F5-846E-4216-AB9A-5B2DBF7124E6 Q47549097-EC473687-7CB4-459A-888E-BC8D1FD171C5 Q47551875-2B7616B9-A2FD-4470-8EA5-0C4CBF04A00E Q47558217-80859DE7-B807-4716-8FDF-F350A0FC5B21 Q47562022-FFDACBEE-3A19-404A-B6B8-A67286F473E9 Q47592202-2EC35199-3BC7-4A3B-9F7C-7886DCED9DAE

P2860

Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.

http://www.wikidata.org/entity/Q35294150

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Dengue viruses are enhanced by ...... tibodies in human immune sera.

@ast

Dengue viruses are enhanced by ...... tibodies in human immune sera.

@en

type

label

Dengue viruses are enhanced by ...... tibodies in human immune sera.

@ast

Dengue viruses are enhanced by ...... tibodies in human immune sera.

@en

prefLabel

Dengue viruses are enhanced by ...... tibodies in human immune sera.

@ast

Dengue viruses are enhanced by ...... tibodies in human immune sera.

@en

P1433

Q35294150-30C32DBA-F41A-4CFD-B7EF-7679E936A556

P1476

Q35294150-72AB3847-4C05-4A3D-BB95-7FE48A2C5A2B

P2093

Q35294150-07BEFDF9-21ED-498B-8EF8-E625A169EB4D

Q35294150-53FABECE-0E32-4C91-8980-4287E11B05DF

Q35294150-DE11D8C0-1B07-4B26-B52C-5F0382789164

Q35294150-E68C0B99-F1DA-4D77-9A0F-E43E9920BB96

Q35294150-EEB34C87-0BBC-4431-828E-ABB7B0C639FD

P2860

Q35294150-05B7A53A-C022-427E-BDCF-282240CCC1DE

Q35294150-07619BA8-A5E1-4CE4-B128-11FC172192AB

Q35294150-08BC25F7-877B-4725-B763-65CEC6187A93

Q35294150-0DEF8702-B9D0-4C24-987D-6D5A23E3CB19

Q35294150-0DFD1FDE-D846-4DA2-BDBD-C58887373E35

Q35294150-0E0D895F-EF73-41A7-A76D-B1218931373A

Q35294150-14AFA320-9EC9-4DF3-AB7B-7C0D5F5545B3

Q35294150-1905310B-0194-4C3D-AAA4-6143416AD470

Q35294150-1ECABA17-CE21-4318-BC65-1500FF74504C

Q35294150-2625B7D2-7935-4817-B93C-FFAFC3624989

P304

Q35294150-AF598809-E870-4604-AA02-FDA9A0BDE6B7

P31

Q35294150-2A0BE2BB-9C1D-4F9F-BB5C-F2BA0D926AC3

P356

Q35294150-5FCBFA68-9A82-43B9-96B9-0409C38E0558

P433

Q35294150-4C3CA086-71F4-42BF-9478-249048DA6B95

P478

Q35294150-FF3954FA-E892-4C15-83E3-BAE5E30C9AD6

P50

Q35294150-7A0EE1D8-2F3A-4040-97CE-F5C0B9C0495E

Q35294150-9BF719FF-3E2C-4331-8A38-4F12D70B201D

Q35294150-A844CC1B-7109-4BAA-AE19-85830AB3D16F

Q35294150-E7E190EF-E11F-413F-8155-77CD59A8E960

Q35294150-F4074EED-1093-4420-B95F-BBB21CAF3177

Q35294150-FC524408-1D74-410E-828E-49E454713C88

P577

Q35294150-DE818B2F-3990-4FAD-88E0-1593850751D7

P5875

Q35294150-4E6F46E9-3E4E-4116-BD4B-F3969667DFE7

P698

Q35294150-E9053E5B-027A-4E79-8652-89D10C7D64F1

P921

Q35294150-4E5B8802-F563-4530-8BBD-95F3ABAC84B1

Q35294150-F835FF0F-1FB0-4106-B8CA-633BF3154FE4

P932

Q35294150-7948585B-9A1B-4115-B777-6B4184DDF597

P356

JOURNAL.PPAT.1004386

P1433

P1476

Dengue viruses are enhanced by ...... tibodies in human immune sera.

@en

P2093

Bhumi Patel

http://www.w3.org/2001/XMLSchema#string

Chih-Yun Lai

http://www.w3.org/2001/XMLSchema#string

Katherine L Williams

http://www.w3.org/2001/XMLSchema#string

Ruklanthi de Alwis

http://www.w3.org/2001/XMLSchema#string

Scott A Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse

The global distribution and burden of dengue

Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention

Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered

Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification

New mouse model for dengue virus vaccine testing

Differential Enhancement of Dengue Virus Immune Complex Infectivity Mediated by Signaling-Competent and Signaling-Incompetent Human Fc RIA (CD64) or Fc RIIA (CD32)

Murine Model for Dengue Virus-Induced Lethal Disease with Increased Vascular Permeability

Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II

A Mouse-Passaged Dengue Virus Strain with Reduced Affinity for Heparan Sulfate Causes Severe Disease in Mice by Establishing Increased Systemic Viral Loads

P304

e1004386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.1004386

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Aravinda de Silva

James E. Crowe Jr.

Michael A Schmid

Ruklanthi de Alwis

P577

2014-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266572802

http://www.w3.org/2001/XMLSchema#string

P698

25275316

http://www.w3.org/2001/XMLSchema#string

P921

P932

4183589

http://www.w3.org/2001/XMLSchema#string